Neurologic Immune-Related Adverse Events with Immune Checkpoint Inhibitor Therapy for Melanoma

Development of a neurologic immune-related adverse event was associated with longer survival.

Therapy with immune checkpoint inhibitors (ICIs) has revolutionized the treatment a wide variety of cancers, including melanoma. However, ICIs have been associated with a variety of immune-related adverse events (irAEs), including those of the nervous system (nirAEs; NEJM JW Neurol 2017 Oct 31 and JAMA Neurol 2017; 74:1216 and Neurology 2017; 89:1127). To explore the association of patient age with development of a nirAE and the association of nirAEs with survival outcomes, researchers in Israel performed a retrospective, single-center study of patients treated with ICI therapy for melanoma over a 7-year period.

Among 937 ICI-treated patients, 76 (8%) developed a nirAE, most commonly myositis (40% of nirAEs), encephalitis (11%), and neuropat…

Reviewing Author

John C. Probasco, MD

Disclosures

Grant/Research Support Genetech/Roche

Editorial BoardsThe Neurohospitalist

Leadership Positions in Professional SocietiesNeurohospitalist Society (President; Chair, Research Subcommittee)

John C. Probasco, MD

Disclosures

Grant/Research Support Genetech/Roche

Editorial BoardsThe Neurohospitalist

Leadership Positions in Professional SocietiesNeurohospitalist Society (President; Chair, Research Subcommittee)

Neurologic Immune-Related Adverse Events with Immune Checkpoint Inhibitor Therapy for Melanoma

Topics

Reviewing Author